Abilify Adds Bipolar Maintenance Claim And Cerebrovascular Warning

Bristol-Myers Squibb/Otsuka's atypical antipsychotic becomes second drug in class, after Lilly's Zyprexa, with bipolar maintenance indication. Abilify also joins Zyprexa and J&J's Risperdal with warning on cerebrovascular adverse events in elderly dementia patients.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet